NCR + ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures

Nature Communications

Volumn 6, Issue , 2015, Pages

  Carrega, Paolo ^a   Loiacono, Fabrizio ^a   Di Carlo, Emma ^b   Scaramuccia, Angelo ^c   Mora, Marco ^c   Conte, Romana ^c   Benelli, Roberto ^c   Spaggiari, Grazia Maria ^d   Cantoni, Claudia ^a,d   Campana, Stefania ^e   Bonaccorsi, Irene ^e   Morandi, Barbara ^d   Truini, Mauro ^c   Mingari, Maria Cristina ^c,d   Moretta, Lorenzo ^f   Ferlazzo, Guido ^e,g  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; GAMMA INTERFERON; INNATE LYMPHOID CELL 3 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 8; NATURAL CYTOTOXICITY RECEPTOR; ONCOPROTEIN; PROTEIN P44; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; CHEMOKINE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR;

CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; TUMOR;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER STAGING; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FIBROBLAST; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; LYMPHOID TISSUE; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; IMMUNOLOGY; LUNG TUMOR; LYMPHOCYTE; METABOLISM; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMOKINES; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; RECEPTORS, NATURAL CYTOTOXICITY TRIGGERING;

EID: 84942474865     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9280     Document Type: Article

References (59)

1. Spits, H. & Cupedo, T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu. Rev. Immunol. 30, 647-675 (2012).
2. Artis, D. & Spits, H. The biology of innate lymphoid cells. Nature 517, 293-301 (2015).
3. Moretta, L. & Moretta, A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 23, 255-259 (2004).
4. Moretta, A. et al. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14, 619-648 (1996).
5. Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495-502 (2008).
6. Sivori, S. et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur. J. Immunol. 29, 1656-1666 (1999).
7. Pende, D. et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190, 1505-1516 (1999).
8. Vitale, M. et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187, 2065-2072 (1998).
9. Moretta, A. et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197-223 (2001).
10. Kruse, P. H., Matta, J., Ugolini, S. & Vivier, E. Natural cytotoxicity receptors and their ligands. Immunol. Cell Biol. 92, 221-229 (2014).
11. Pogge von Strandmann, E. et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27, 965-974 (2007).
12. Brandt, C. S. et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495-1503 (2009).
13. Baychelier, F. et al. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 122, 2935-2942 (2013).
14. Walker, J. A., Barlow, J. L. & McKenzie, A. N. Innate lymphoid cells-how did we miss them? Nat. Rev. Immunol. 13, 75-87 (2013).
15. Eberl, G., Di Santo, J. P. & Vivier, E. The brave new world of innate lymphoid cells. Nat. Immunol. 16, 1-5 (2015).
16. Robinette, M. L. et al. Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat. Immunol. 16, 306-317 (2015).
17. Montaldo, E. et al. Human RORgammat(+)CD34(+) cells are lineage-specified progenitors of group 3 RORgammat(+) innate lymphoid cells. Immunity 41, 988-1000 (2014).
18. Cella, M. et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457, 722-725 (2009).
19. Cupedo, T. et al Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC + CD127+ natural killer-like cells. Nat. Immunol. 10, 66-74 (2009).
20. Hughes, T. et al. Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood 113, 4008-4010 (2009).
21. Vacca, P. et al. Identification of diverse innate lymphoid cells in human decidua. Mucosal. Immunol. 8, 254-264 (2014).
22. Fuchs, A. et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15-responsive IFN-gamma-producing cells. Immunity 38, 769-781 (2013).
23. Luci, C. et al. Influence of the transcription factor RORgammat on the development of NKp46 + cell populations in gut and skin. Nat. Immunol. 10, 75-82 (2009).
24. Sanos, S. L. et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat. Immunol. 10, 83-91 (2009).
25. Satoh-Takayama, N. et al. Microbial flora drives interleukin 22 production in intestinal NKp46 + cells that provide innate mucosal immune defense. Immunity 29, 958-970 (2008).
26. Spits, H. et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145-149 (2013).
27. Satoh-Takayama, N. et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46 + cell subsets from Id2-dependent precursors. J. Exp. Med. 207, 273-280 (2010).
28. Vonarbourg, C. et al. Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) innate lymphocytes. Immunity 33, 736-751 (2010).
29. Ota, N. et al. IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with Citrobacter rodentium. Nat. Immunol. 12, 941-948 (2011).
30. Glatzer, T. et al. RORgammat(+) innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity 38, 1223-1235 (2013).
31. Crellin, N. K., Trifari, S., Kaplan, C. D., Cupedo, T. & Spits, H. Human NKp44 + IL-22 + cells and LTi-like cells constitute a stable RORC + lineage distinct from conventional natural killer cells. J. Exp. Med. 207, 281-290 (2010).
32. Aloisi, F. & Pujol-Borrell, R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6, 205-217 (2006).
33. Ruddle, N. H. Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. Immunol. Res. 19, 119-125 (1999).
34. Drayton, D. L., Liao, S., Mounzer, R. H. & Ruddle, N. H. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7, 344-353 (2006).
35. van de Pavert, S. A. & Mebius, R. E. New insights into the development of lymphoid tissues. Nat. Rev. Immunol. 10, 664-674 (2010).
36. Mebius, R. E. Organogenesis of lymphoid tissues. Nat. Rev. Immunol. 3, 292-303 (2003).
37. Ulrichs, T. et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J. Pathol. 204, 217-228 (2004).
38. Hogg, J. C. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl. J. Med. 350, 2645-2653 (2004).
39. Rangel-Moreno, J. et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12, 639-646 (2011).
40. Dieu-Nosjean, M. C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410-4417 (2008).
41. Shields, J. D., Kourtis, I. C, Tomei, A. A., Roberts, J. M. & Swartz, M. A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328, 749-752 (2010).
42. Carrega, P. et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 112, 863-875 (2008).
43. Koch, J., Steinle, A., Watzl, C. & Mandelboim, O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 34, 182-191 (2013).
44. Balsamo, M. et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl Acad. Sci. USA 106, 20847-20852 (2009).
45. Horn, L., Pao, W. & Johnson, D. H. in Harrison's Principles of Internal Medicine. edn. 18th (eds Longo, D. L. et al.) (McGraw-Hill, 2012).
46. Rami-Porta, R., Crowley, J. J. & Goldstraw, P. The revised TNM staging system for lung cancer. Ann. Thorac. Cardiovasc. Surg. 15, 4-9 (2009).
47. Sautes-Fridman, C. et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev. 30, 13-25 (2011).
48. Carrega, P. et al. CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J. Immunol. 192, 3805-3815 (2014).
49. Kirchberger, S. et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210, 917-931 (2013).
50. Germain, C. et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189, 832-844 (2014).
51. Serafini, N., Vosshenrich, C. A. & Di Santo, J. P. Transcriptional regulation of innate lymphoid cell fate. Nat. Rev. Immunol. 15, 415-428 (2015).
52. Waugh, D. J. & Wilson, C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14, 6735-6741 (2008).
53. Smith, K. A. Interleukin-2: inception, impact, and implications. Science 240, 1169-1176 (1988).
54. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
55. Tesar, B. M. et al. Direct antigen presentation by a xenograft induces immunity independently of secondary lymphoid organs. J. Immunol. 173, 4377-4386 (2004).
56. Kirk, C. J., Hartigan-O'Connor, D. & Mule, J. J. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 61, 8794-8802 (2001).
57. Eisenring, M., vom Berg, J., Kristiansen, G., Saller, E. & Becher, B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat. Immunol. 11, 1030-1038 (2010).
58. Wolk, K. et al. IL-22 increases the innate immunity of tissues. Immunity 21, 241-254 (2004).
59. Spaggiari, G. M. et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 111, 1327-1333 (2008).